Ariana Pelosci

Results from the phase 1 ARROS-1 trial showed NVL-520 may stop tumor growth and yielded response in brain metastases in patients with ROS1-positive non–small cell lung cancer and other solid tumors.

An abbreviated new drug application was granted approval by the FDA for leuprolide acetate injection for patients with advanced prostate cancer.

A recent study found that giving sinoatrial node radiation therapy during chemoradiotherapy may increase the likelihood of atrial fibrillation in patients with small cell lung cancer and non–small cell lung cancer.

At ASTRO 2022, Phuoc Tho Tran, MD, spoke about the potential benefit of combining salvage radiation therapy and enzalutamide vs placebo in patients with high-risk prostate-specific antigen–recurrent prostate cancer after radical prostatectomy.

Based on results from the phase 1/2 MajesTec-1 trial, the FDA has granted accelerated approval to teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.

Results from the phase 2 NRG-HN004 trial found durvalumab plus radiotherapy did not show improved progression-free survival vs cetuximab in patients with locoregionally advanced head and neck cancer who had a contraindication to cisplatin.

Based on results from the phase 3 HIMALAYA trial, the FDA has approved tremelimumab plus durvalumab in patients with unresectable hepatocellular carcinoma.

Across various cancer types, stereotactic ablative body radiotherapy was found to be a safe method for treating oligometastes.

Results from the phase 2 CheckPAC trial indicated that stereotactic body radiotherapy plus nivolumab and ipilimumab produced a promising clinical benefit rate for patients with refractory metastatic pancreatic cancer.

A meta-analysis found Black men who undergo radiotherapy for localized prostate cancer have better outcomes in terms of biochemical recurrence, distant metastases, and prostate cancer-specific mortality than White men despite presenting with more aggressive disease.

Tycel Phillips, MD, reviewed effective second-line treatment options for patients with relapsed/refractory mantle cell lymphoma.

A panel of experts convened at the 2022 NCCN: Hematologic Malignancies Conference to discuss the classification, treatment options, and supportive care strategies available for patients with acute myeloid leukemia.

GPRC5D appears to be an active, promising target for CAR T-cell product MCARH109 in heavily pretreated multiple myeloma.

During Breast Cancer Awareness Month, CancerNetwork® spoke with Megan May, PharmD, about her role as a pharmacist on a multidisciplinary cancer care team.

Findings from a study examining the prognostic value of Nutritional Risk Index prior to hematopoietic stem cell transplant in patients with acute myeloid leukemia highlighted a need to consider other tools for assessing nutritional status among those undergoing transplant.

Patients with KRAS G12C–mutant non–small cell lung cancer may benefit from BBP-398 plus sotorasib, which received fast track designation from the FDA.

Based on results from the phase 3 TROPiCS trial, the FDA has granted priority review to sacituzumab govitecan-hziy for unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer.

Jun J. Mao, MD, MSCE, spoke about updated guidelines from ASCO and SIO for pain management in patients with cancer.

After review by an independent data monitoring committee, the phase 2 ENVASARC trial, analyzing envafolimab monotherapy or in combination with ipilimumab for patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma, will proceed as planned.

Patients with metastatic colorectal cancer who were below a certain income level appear to be more susceptible to major financial hardship.

The PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody was approved by the FDA as a companion diagnostic to help identify patients with HER2-low metastatic breast cancer who may be eligible to receive fam-trastuzumab deruxtecan-nxki.

Minimal residual disease negativity might be an important prognostic indicator in patients with newly diagnosed multiple myeloma, investigators say.

Receipt of red blood cell transfusions can negatively impact survival outcomes in patients with endometrial cancers, while ovarian cancers were most affected by preoperative global health status.

CUE-101 alone or in combination with pembrolizumab was granted fast track designation by the FDA for patients with human papillomavirus 16–positive recurrent/metastatic head and neck squamous cell carcinoma.

Fast track designation was granted to sapanisertib by the FDA for patients with unresectable or metastatic squamous cell non–small cell lung cancer who have an NRF2 mutation.

A recent study presented at IGCS 2022 looking at clinical trial enrollment found that Black patients experienced the biggest increase in accrual following an NCI call-to-action for more diversity in clinical trials.

Despite inconclusive efficacy results regarding the use of pembrolizumab plus epacadostat in patients with recurrent clear cell ovarian carcinoma, rapid accrual to the trial reveals an unmet need in this cancer subset.

Results from the phase 3 TRITON3 trial demonstrated that radiographic progression-free survival was significantly improved when patients with metastatic castration-resistant prostate cancer were treated with rucaparib monotherapy vs physician’s choice.

A real-world study found that time to discontinuation and time to next treatment outcomes associated with ibrutinib were not impacted by a baseline high risk of atrial fibrillation or stroke in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma.

Based on results from a phase 3 trial, a bevacizumab biosimilar, bevacizumab-adcd, was approved by the FDA for patients with metastatic or recurrent non-squamous non–small cell lung in addition to 5 other disease types.